COSCIENS BIOPHARMA INC (CSCI.CA) Stock Fundamental Analysis
Canada - TSX:CSCI - CA22112H1010 - Common Stock
3.42 CAD
-0.03 (-0.87%)
Overall CSCI gets a fundamental rating of 3 out of 10. We evaluated CSCI against 22 industry peers in the Biotechnology industry. CSCI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CSCI is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CSCI has reported negative net income.
CSCI had a negative operating cash flow in the past year.
CSCI had negative earnings in each of the past 5 years.
CSCI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CSCI has a better Return On Assets (-68.37%) than 68.18% of its industry peers.
With a decent Return On Equity value of -265.49%, CSCI is doing good in the industry, outperforming 63.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.37% | ||
| ROE | -265.49% | ||
| ROIC | N/A |
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CSCI has a Gross Margin of 46.84%. This is in the better half of the industry: CSCI outperforms 77.27% of its industry peers.
In the last couple of years the Gross Margin of CSCI has grown nicely.
CSCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.84% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
2. Health
2.1 Basic Checks
CSCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CSCI has been increased compared to 1 year ago.
Compared to 5 years ago, CSCI has more shares outstanding
Compared to 1 year ago, CSCI has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of -1.55, we must say that CSCI is in the distress zone and has some risk of bankruptcy.
CSCI's Altman-Z score of -1.55 is fine compared to the rest of the industry. CSCI outperforms 68.18% of its industry peers.
A Debt/Equity ratio of 0.29 indicates that CSCI is not too dependend on debt financing.
CSCI has a Debt to Equity ratio (0.29) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.55 |
ROIC/WACCN/A
WACC7.49%
2.3 Liquidity
CSCI has a Current Ratio of 2.98. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 2.98, CSCI is doing good in the industry, outperforming 68.18% of the companies in the same industry.
CSCI has a Quick Ratio of 2.65. This indicates that CSCI is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.65, CSCI is doing good in the industry, outperforming 68.18% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.98 | ||
| Quick Ratio | 2.65 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 11.52% over the past year.
The Revenue has grown by 109.13% in the past year. This is a very strong growth!
The Revenue has been growing by 80.53% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)11.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.82%
Revenue 1Y (TTM)109.13%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%17.63%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CSCI. In the last year negative earnings were reported.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
CSCI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:CSCI (11/7/2025, 7:00:00 PM)
3.42
-0.03 (-0.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners8.93%
Inst Owner ChangeN/A
Ins Owners1.45%
Ins Owner ChangeN/A
Market Cap11.12M
Revenue(TTM)9.44M
Net Income(TTM)-18.84M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.83 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.11 | ||
| P/tB | 1.11 | ||
| EV/EBITDA | N/A |
EPS(TTM)-8.48
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-7.9
FCFYN/A
OCF(TTM)-7.43
OCFYN/A
SpS4.1
BVpS3.08
TBVpS3.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.37% | ||
| ROE | -265.49% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 46.84% | ||
| FCFM | N/A |
ROA(3y)-32.96%
ROA(5y)-24.63%
ROE(3y)-65.43%
ROE(5y)-50.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.48%
GM growth 5Y19.79%
F-Score3
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.29 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 74.44% | ||
| Cap/Sales | 11.69% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.98 | ||
| Quick Ratio | 2.65 | ||
| Altman-Z | -1.55 |
F-Score3
WACC7.49%
ROIC/WACCN/A
Cap/Depr(3y)43.14%
Cap/Depr(5y)N/A
Cap/Sales(3y)7.47%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.82%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)109.13%
Revenue growth 3Y21.84%
Revenue growth 5Y80.53%
Sales Q2Q%17.63%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-8.81%
OCF growth 3YN/A
OCF growth 5YN/A
COSCIENS BIOPHARMA INC / CSCI.CA FAQ
What is the fundamental rating for CSCI stock?
ChartMill assigns a fundamental rating of 3 / 10 to CSCI.CA.
What is the valuation status of COSCIENS BIOPHARMA INC (CSCI.CA) stock?
ChartMill assigns a valuation rating of 0 / 10 to COSCIENS BIOPHARMA INC (CSCI.CA). This can be considered as Overvalued.
How profitable is COSCIENS BIOPHARMA INC (CSCI.CA) stock?
COSCIENS BIOPHARMA INC (CSCI.CA) has a profitability rating of 2 / 10.
How financially healthy is COSCIENS BIOPHARMA INC?
The financial health rating of COSCIENS BIOPHARMA INC (CSCI.CA) is 4 / 10.